BeiGene, Ltd. (NASDAQ:BGNE) – Research analysts at William Blair issued their Q4 2017 EPS estimates for shares of BeiGene in a research note issued to investors on Tuesday. William Blair analyst Y. Xu anticipates that the company will earn ($1.88) per share for the quarter. William Blair also issued estimates for BeiGene’s Q1 2018 earnings at ($2.11) EPS, Q2 2018 earnings at ($2.14) EPS, Q3 2018 earnings at ($2.18) EPS, Q4 2018 earnings at ($1.12) EPS and FY2018 earnings at ($7.56) EPS.
BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Monday, November 13th. The company reported $2.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.23 by $2.31. The firm had revenue of $220.21 million during the quarter, compared to the consensus estimate of $1.55 million. During the same quarter in the previous year, the firm earned ($1.08) EPS. TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/11/18/beigene-ltd-to-post-q4-2017-earnings-of-1-88-per-share-william-blair-forecasts-bgne.html.
BeiGene (BGNE) opened at $84.18 on Friday. BeiGene has a one year low of $26.43 and a one year high of $118.95. The company has a quick ratio of 8.38, a current ratio of 8.38 and a debt-to-equity ratio of 0.57.
In other news, CMO Amy C. Peterson sold 3,601 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $82.96, for a total value of $298,738.96. Following the transaction, the chief marketing officer now owns 1,201 shares in the company, valued at approximately $99,634.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Oyler sold 25,054 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $83.06, for a total transaction of $2,080,985.24. Following the completion of the transaction, the chief executive officer now owns 491,891 shares in the company, valued at approximately $40,856,466.46. The disclosure for this sale can be found here. Insiders have sold a total of 179,612 shares of company stock worth $14,531,763 in the last 90 days. Company insiders own 19.90% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in BGNE. Parametric Portfolio Associates LLC increased its holdings in BeiGene by 59.1% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,796 shares of the company’s stock worth $395,000 after acquiring an additional 4,010 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in BeiGene in the 1st quarter worth approximately $238,000. Bank of America Corp DE increased its holdings in BeiGene by 5.8% in the 1st quarter. Bank of America Corp DE now owns 20,199 shares of the company’s stock worth $740,000 after acquiring an additional 1,116 shares in the last quarter. Bank of Montreal Can increased its holdings in BeiGene by 315.2% in the 2nd quarter. Bank of Montreal Can now owns 18,610 shares of the company’s stock worth $837,000 after acquiring an additional 14,128 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D increased its holdings in BeiGene by 6.2% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 48,831 shares of the company’s stock worth $2,197,000 after acquiring an additional 2,844 shares in the last quarter. 52.09% of the stock is owned by institutional investors.
BeiGene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
What are top analysts saying about BeiGene Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BeiGene Ltd. and related companies.